<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
NBIX
Neurocrine
$
()


  • Neurocrine price target raised by $31 at UBS, here's why

    2/20/2024 - 07:31am
  • Neurocrine price target raised by $7 at Guggenheim, here's why

    2/12/2024 - 07:57am
  • Neurocrine price target raised by $1 at Deutsche Bank, here's why

    2/8/2024 - 08:59am
  • Neurocrine price target raised by $6 at Piper Sandler, here's why

    2/8/2024 - 07:33am
  • Neurocrine price target raised to $154 from $150 at Canaccord

    2/8/2024 - 07:17am
  • Neurocrine price target raised by $24 at Mizuho, here's why

    2/8/2024 - 06:46am
  • Neurocrine price target raised by $13 at Wells Fargo, here's why

    2/8/2024 - 06:17am
  • Neurocrine price target lowered by $1 at Citi, here's why

    2/8/2024 - 05:53am
  • Neurocrine trading resumes

    2/7/2024 - 09:40am
  • Neurocrine trading halted, volatility trading pause

    2/7/2024 - 09:35am
  • Neurocrine sees FY24 INGREZZA net product sales $2.1B-$2.2B

    2/7/2024 - 07:03am
  • Neurocrine reports Q4 adjusted EPS $1.54, consensus $1.14

    2/7/2024 - 07:02am
  • Neurocrine price target raised by $5 at Barclays, here's why

    1/22/2024 - 07:55am
  • Neurocrine director Lyons, Chief Medical Officer Roberts sell $1.3M in stock

    12/27/2023 - 16:20pm
  • Neurocrine price target raised by $20 at Barclays, here's why

    12/19/2023 - 14:03pm
dynamic_feed Breaking News